Navigation Links
Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
Date:2/27/2008

All children 6 months to 18 years of age recommended for annual vaccination

ATLANTA, Feb. 27 /PRNewswire/ -- The National Foundation for Infectious Diseases' Childhood Influenza Immunization Coalition (CIIC) is pleased to support today's vote by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) to expand the influenza vaccine recommendation for children 6 months up to 18 years of age. This recommendation is to be implemented as soon as feasible and no later than the 2009/10 influenza season.

"Each season many children remain vulnerable to the consequences of not being vaccinated against influenza," said Richard H. Carmona, M.D., M.P.H., FACS, CIIC Chair, 17th Surgeon General of the United States (2002-2006), President of Canyon Ranch Institute and Distinguished Professor of Public Health, The University of Arizona Mel and Enid Zuckerman College of Public Health. "We hope this expanded vaccination recommendation will strongly encourage Americans to get an annual influenza vaccination as soon as vaccine becomes available in their communities. This will help in reducing the number of childhood hospitalizations and deaths from influenza each season."

Influenza is a serious and potentially deadly disease that spreads very easily. Anyone can get influenza, but rates of infection are highest among children. Currently, the recommendation calls for annual vaccination of children 6 months up to 5 years of age. Vaccination is especially beneficial to both children and adults with certain chronic medical conditions like asthma, diabetes, heart disease and compromised immune systems. Not only are children at risk for influenza when unvaccinated, but infected children often transmit influenza to other vulnerable populations, such as grandparents and other caregivers age 50 and over. An expanded vaccination recommendation means greater protection for children and for the community at large.

"The Coalition welcomes ACIP's recommendation as we continue to educate the health care community and the general public about the severity of influenza," said Carol J. Baker, M.D., FAAP, FIDSA, CIIC Moderator, NFID President and Professor of Pediatrics, Molecular Virology and Microbiology, Baylor College of Medicine. "Influenza is very serious, but it is vaccine- preventable. Annual vaccination of children of all ages is the best way to protect children and interrupt virus transmission to others."

A Coalition report available on http://www.PreventChildhoodInfluenza.org outlines key strategies for health care professionals to help ensure all recommended children are vaccinated: offering influenza vaccination at all medical visits and making use of the entire influenza season -- vaccinating as soon as vaccine is available and continuing to vaccinate in January, February and beyond.

About the Childhood Influenza Immunization Coalition

The National Foundation for Infectious Diseases' (NFID) Childhood Influenza Immunization Coalition (CIIC) was established to protect infants, children and adolescents from influenza by communicating with "one strong voice" the need to make influenza immunization a national health priority. CIIC members represent 25 of the nation's leading public health, medical, patient and parent groups committed to protecting children's health and encouraging wellness.

The Childhood Influenza Immunization Coalition initiatives are made possible through an unrestricted educational grant to NFID from sanofi pasteur.

For more information on CIIC or childhood influenza, please visit http://www.preventchildhoodinfluenza.org.

Contact: Jennifer Corrigan

732-382-8898

732-742-7148 (Cell phone)


'/>"/>
SOURCE The National Foundation for Infectious Diseases
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. More than $6 Million Raised During Two-Day Event to Support Research and Treatment for Childhood Cancer and Other Catastrophic Diseases
2. NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza
3. GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicology Studies
4. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
5. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
6. Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated
7. Vical Presentation at Military Pandemic Influenza Workshop
8. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
9. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
10. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
11. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
Breaking Biology Technology:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
Breaking Biology News(10 mins):